Is Danaher Stock Underperforming the Nasdaq?

Is Danaher Stock Underperforming the Nasdaq?

Mon, August 31, 2026 at 5:34 PM GMT+3 3 min read

• DHR -3.10%
• ^IXIC -1.03%

Washington, the District Of Columbia-based Danaher Corporation (DHR) designs, manufactures, and markets professional, medical, research, and industrial products and services. The company is valued at $151.9 billion by market cap.

Companies worth $10 billion or more are generally described as "large-cap stocks," and DHR definitely fits that description, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the diagnostics & research industry. DHR's competitive strengths come from its portfolio of high-margin, mission-critical tools in biotech, diagnostics, and life sciences. Strong positions in regulated, R&D-heavy markets give it pricing power and resilience, even in downturns.

More News from Barchart

Despite its notable strength, DHR shares slipped 11% from their 52-week high of $242.80, achieved on Jan. 22. Over the past three months, DHR stock has gained 19.6%, outperforming the Nasdaq Composite's ($NASX) 1.9% dip during the same time frame.

Shares of DHR fell 5.6% on a YTD basis but climbed 5.3% over the past 52 weeks, underperforming NASX's YTD gains of 13.6% and 21.6% returns over the last year.

To confirm the bullish trend, DHR has been trading above its 50-day moving average since early June, with some fluctuations. It is trading above its 200-day moving average since early August, with slight fluctuations.

DHR lagged mainly because of a slowdown in respiratory testing, while sentiment took an additional hit from softer-than-anticipated biotech sales more than $100 million in bioprocessing revenue slipped into next year due to timing of shipments, despite mid-teens growth in orders.

On Jul. 21, DHR shares tumbled 11% after reporting its Q2 results. Its adjusted EPS of $1.94 beat Wall Street expectations of $1.84. The company's revenue was $6.3 billion, surpassing Wall Street forecasts of $6.1 billion. DHR expects full-year adjusted EPS in the range of $8.45 to $8.60.

In the competitive arena of diagnostics & research, Revvity, Inc. (RVTY) has taken the lead over DHR, showing resilience with a 33.1% uptick on a YTD basis and 44.4% gains over the past 52 weeks.

Wall Street analysts are bullish on DHR's prospects. The stock has a consensus "Strong Buy" rating from the 24 analysts covering it, and the mean price target of $223.09 suggests a potential upside of 3.2% from current price levels.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com